# SAFETY DATA SHEET



Seahorse XF Hu T Cell Activation Assay Kit

## **Section 1. Identification**

Product identifier : Seahorse XF Hu T Cell Activation Assay Kit

Part no. (chemical kit) : 103759-100, 103766-100

 Part no.
 : Z-deoxyglucose (2-DG)
 103761-000

 ImmunoCult™ Human CD3/CD28 T Cell
 103760-000

Activator

Relevant identified uses of the substance or mixture and uses advised against

**Identified uses** : For research use only.

Z-deoxyglucose (2-DG) 2 x 246.24 mg ImmunoCult™ Human CD3/CD28 T Cell 1 x 2 ml

Activator

**Uses advised against**: Not for use in diagnostic procedures (RUO).

Supplier/Manufacturer : Agilent Technologies Australia Pty Ltd

679 Springvale Road

Mulgrave

Victoria 3170, Australia

1800 802 402

Emergency telephone number (with hours of

operation)

: CHEMTREC®: +(61)-290372994

## Section 2. Hazard(s) identification

### Classification of the substance or mixture

Not classified.

ImmunoCult™ Human Percentage of the mixture consisting of ingredient(s) CD3/CD28 T Cell Activator of unknown hazards to the aquatic environment: 1.2%

**GHS label elements** 

Signal word : Z-deoxyglucose (2-DG) No signal word.
ImmunoCult™ Human No signal word.

CD3/CD28 T Cell Activator

Hazard statements : Z-deoxyglucose (2-DG) No known significant effects or critical hazards. No known significant effects or critical hazards. No known significant effects or critical hazards.

CD3/CD28 T Cell Activator

**Precautionary statements** 

Prevention : 2-deoxyglucose (2-DG) Not applicable.

ImmunoCult™ Human Not applicable. CD3/CD28 T Cell Activator

Response : Z-deoxyglucose (2-DG) Not applicable.
ImmunoCult™ Human Not applicable.

CD3/CD28 T Cell Activator

Storage : 2-deoxyglucose (2-DG) Not applicable. ImmunoCult™ Human Not applicable.

CD3/CD28 T Cell Activator

Disposal : Z-deoxyglucose (2-DG) Not applicable.

ImmunoCult™ Human Not applicable.

CD3/CD28 T Cell Activator

Supplemental label elements

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 1/12

Seahorse XF Hu T Cell Activation Assay Kit

# Section 2. Hazard(s) identification

Additional warning phrases

: Z-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator Not applicable. Not applicable.

Other hazards which do not result in classification

Z-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator None known. None known.

## Section 3. Composition and ingredient information

Substance/mixture

: **Z**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator

Substance Mixture

#### **CAS** number/other identifiers

Ingredient name	% (w/w)	CAS number		
2-deoxyglucose (2-DG)				
2-deoxy-D-glucose	100	154-17-6		

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

The total concentration of ingredients in this product, reported or not in this section, is 100%.

Occupational exposure limits, if available, are listed in Section 8.

### Section 4. First aid measures

Description of necessary first aid measures
---

**Eye contact** : **2**-deoxyglucose (2-DG)

Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get

medical attention if irritation occurs.

ImmunoCult™ Human CD3/CD28 T Cell Activator Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get

medical attention if irritation occurs.

**Inhalation** : **2**-deoxyglucose (2-DG)

Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical

attention if symptoms occur.

ImmunoCult™ Human CD3/CD28 T Cell Activator Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be

delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Skin contact : 2-deoxyglucose (2-DG)

Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get

medical attention if symptoms occur.

ImmunoCult™ Human CD3/CD28 T Cell Activator Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get

medical attention if symptoms occur.

**Ingestion** : **2**-deoxyglucose (2-DG)

Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce

small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

ImmunoCult™ Human

CD3/CD28 T Cell Activator

Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 2/12

## Section 4. First aid measures

vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

#### Most important symptoms/effects, acute and delayed

Potential acute health effects

Eye contact : Z-deoxyglucose (2-DG) No known significant effects or critical hazards. No known significant effects or critical hazards. No known significant effects or critical hazards.

CD3/CD28 T Cell Activator

Inhalation: Z-deoxyglucose (2-DG)No known significant effects or critical hazards.ImmunoCult™ HumanNo known significant effects or critical hazards.

CD3/CD28 T Cell Activator

Skin contact : Z-deoxyglucose (2-DG) No known significant effects or critical hazards. No known significant effects or critical hazards. No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 T Cell Activator

Ingestion : Z-deoxyglucose (2-DG) No known significant effects or critical hazards.

ImmunoCult™ Human No known significant effects or critical hazards. CD3/CD28 T Cell Activator

Over-exposure signs/symptoms

Eye contact : Z-deoxyglucose (2-DG) No specific data.
ImmunoCult™ Human No specific data.

CD3/CD28 T Cell Activator

Inhalation : Z-deoxyglucose (2-DG) No specific data.

ImmunoCult™ Human No specific data. CD3/CD28 T Cell Activator

Skin contact : Z-deoxyglucose (2-DG) No specific data.

ImmunoCult™ Human No specific data.
CD3/CD28 T Cell Activator

Ingestion : 2-deoxyglucose (2-DG) No specific data.
ImmunoCult™ Human No specific data.

ImmunoCult™ Human No specific CD3/CD28 T Cell Activator

#### Indication of immediate medical attention and special treatment needed, if necessary

Notes to physician : Z-deoxyglucose (2-DG) Treat symptomatically. Contact poison treatment

specialist immediately if large quantities have been

ingested or inhaled.

ImmunoCult™ Human In case of inhalation of decomposition products in a

CD3/CD28 T Cell Activator fire, symptoms may be delayed. The exposed person may need to be kept under medical

surveillance for 48 hours.

Specific treatments : Z-deoxyglucose (2-DG) No specific treatment.

No specific treatment.

No specific treatment.

ImmunoCult™ Human No specific treatment.
CD3/CD28 T Cell Activator

Protection of first-aiders : Z-deoxyglucose (2-DG) No action shall be taken involving any personal risk

or without suitable training.
ImmunoCult™ Human No action shall be taken involving any personal risk

ImmunoCult Human No action shall be taken involving any personal risk CD3/CD28 T Cell Activator or without suitable training.

See toxicological information (Section 11)

## Section 5. Firefighting measures

**Extinguishing media** 

**Suitable extinguishing**: **Z**-deoxyglucose (2-DG)

Use an extinguishing agent suitable for the surrounding fire.

ImmunoCult™ Human Use an extinguishing agent suitable for the CD3/CD28 T Cell Activator surrounding fire.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 3/12

## Section 5. Firefighting measures

Unsuitable extinguishing media

: 2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator None known. None known.

Specific hazards arising from the chemical

2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator No specific fire or explosion hazard.

In a fire or if heated, a pressure increase will occur

and the container may burst.

**Hazardous thermal** decomposition products **2**-deoxyglucose (2-DG)

Decomposition products may include the following

materials: carbon dioxide carbon monoxide

ImmunoCult™ Human CD3/CD28 T Cell Activator Decomposition products may include the following

materials: carbon dioxide carbon monoxide nitrogen oxides phosphorus oxides

**Special protective actions** for fire-fighters

: **2**-deoxyglucose (2-DG)

Promptly isolate the scene by removing all persons

from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or

without suitable training.

ImmunoCult™ Human CD3/CD28 T Cell Activator Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or

without suitable training.

Special protective equipment for fire-fighters : 2-deoxyglucose (2-DG)

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus

(SCBA) with a full face-piece operated in positive

pressure mode.

ImmunoCult™ Human CD3/CD28 T Cell Activator Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive

pressure mode.

## Section 6. Accidental release measures

#### Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: **2**-deoxyglucose (2-DG)

No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.

ImmunoCult™ Human CD3/CD28 T Cell Activator No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal

protective equipment.

For emergency responders : **2**-deoxyglucose (2-DG)

If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on

suitable and unsuitable materials. See also the information in "For non-emergency personnel". If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on

suitable and unsuitable materials. See also the information in "For non-emergency personnel".

ImmunoCult™ Human CD3/CD28 T Cell Activator

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version: 3.1

### Section 6. Accidental release measures

**Environmental precautions**: **2**-deoxyglucose (2-DG)

Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways,

ImmunoCult™ Human CD3/CD28 T Cell Activator Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

#### Methods and material for containment and cleaning up

Methods for cleaning up

: **2**-deoxyglucose (2-DG)

Move containers from spill area. Vacuum or sweep up material and place in a designated, labelled waste container. Dispose of via a licensed waste disposal contractor.

ImmunoCult™ Human CD3/CD28 T Cell Activator Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

## Section 7. Handling and storage

Precautions for safe handling

**Protective measures** 

: **2**-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell Activator Put on appropriate personal protective equipment (see Section 8).

Put on appropriate personal protective equipment (see Section 8).

areas where this material is handled, stored and

processed. Workers should wash hands and face

Eating, drinking and smoking should be prohibited in

Advice on general occupational hygiene : **2**-deoxyglucose (2-DG)

before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures. Eating, drinking and smoking should be prohibited in

areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

ImmunoCult™ Human CD3/CD28 T Cell Activator

Conditions for safe storage, : 2-deoxyglucose (2-DG) including any incompatibilities

ImmunoCult™ Human CD3/CD28 T Cell Activator Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use. Store in accordance with local regulations. Store in original container protected from direct sunlight in a drv. cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened

Date of issue/Date of revision : 29/04/2024 : 27/10/2023 Version: 3.1 Date of previous issue

## Section 7. Handling and storage

must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

## Section 8. Exposure controls and personal protection

**Control parameters** 

Occupational exposure limits

None.

#### **Biological exposure indices**

No exposure indices known.

# Appropriate engineering controls

**Environmental exposure** controls

- : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
- : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

#### Individual protection measures

**Hygiene measures** 

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period.

Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

**Hand protection** 

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

**Body protection** 

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** 

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

# Section 9. Physical and chemical properties and safety characteristics

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### **Appearance**

**Physical state** 

: **Z**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator

Solid. Liquid. [Clear.]

**Auto-ignition temperature** 

# Section 9. Physical and chemical properties and safety characteristics

characteristics										
Colour	:	Z-deoxyglucose (2-D ImmunoCult™ Huma CD3/CD28 T Cell Ac	nan <sup>´</sup> White.							
Odour	:	Z-deoxyglucose (2-D ImmunoCult™ Huma CD3/CD28 T Cell Ac	Not available. Not available.							
Odour threshold	:	Z-deoxyglucose (2-D ImmunoCult™ Huma CD3/CD28 T Cell Ac	Not available. Not available.							
pH	:	Z-deoxyglucose (2-D ImmunoCult™ Huma CD3/CD28 T Cell Ac	Not available. Not available.							
Melting point/freezing point	:	Z-deoxyglucose (2-D ImmunoCult™ Huma CD3/CD28 T Cell Ac	146 to 147°C (294.8 to 296.6°F) Not available.							
Boiling point, initial boiling point, and boiling range	:	Z-deoxyglucose (2-D ImmunoCult™ Huma CD3/CD28 T Cell Ac	Not available. Not available.							
Flash point	:	Z-deoxyglucose (2-D ImmunoCult™ Huma CD3/CD28 T Cell Ac	Not applicable. Not available.							
Evaporation rate	:	Z-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator								
Flammability	:	Z-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator								
Lower and upper explosion limit/flammability limit	:	P-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator  Not applic								
Vapour pressure	:		Vapoi	ır Pressu	re at 20°C	at 20°C Vapour pressure at 50°C				
		Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method		
		ImmunoCult™ Human CD3/CD28 T Cell Activator								
		water	17.5	2.3	-	92.258	12.3	-		
Relative vapour density	:	Z-deoxyglucose (2-D ImmunoCult™ Huma CD3/CD28 T Cell Ac	cable. able.							
Relative density	:	Z-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator  Not availa								
Solubility(ies)		Media			Result					
		2-deoxyglucose (2- water ImmunoCult™ Hum Cell Activator water	Soluble Soluble							
Partition coefficient: n-octanol/water	:	Z-deoxyglucose (2-DG) Not available. ImmunoCult™ Human Not applicable. CD3/CD28 T Cell Activator								
A 4 1 141 4 4		<b>~</b>	<b>~</b> \							

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 7/12

Not applicable.

: **2**-deoxyglucose (2-DG)

Seahorse XF Hu T Cell Activation Assay Kit

# Section 9. Physical and chemical properties and safety characteristics

**Decomposition temperature** 

Z-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator

Not available. Not available.

**Viscosity** 

: **Z**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator

Not applicable. Not available.

**Particle characteristics** 

Median particle size

: **Z**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator

Not available. Not applicable.

## Section 10. Stability and reactivity

Reactivity

: **2**-deoxyglucose (2-DG)

No specific test data related to reactivity available for this product or its ingredients.

ImmunoCult™ Human CD3/CD28 T Cell Activator

No specific test data related to reactivity available for this product or its ingredients.

**Chemical stability** 

: **Z**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator

The product is stable. The product is stable.

Possibility of hazardous

reactions

: **2**-deoxyglucose (2-DG)

Under normal conditions of storage and use,

hazardous reactions will not occur.

ImmunoCult™ Human CD3/CD28 T Cell Activator Under normal conditions of storage and use,

hazardous reactions will not occur.

**Conditions to avoid** 

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator

No specific data. No specific data.

Incompatible materials

: 2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator May react or be incompatible with oxidising materials. May react or be incompatible with oxidising materials.

Hazardous decomposition

products

: **2**-deoxyglucose (2-DG)

Under normal conditions of storage and use, hazardous decomposition products should not be

produced

ImmunoCult™ Human CD3/CD28 T Cell Activator Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## Section 11. Toxicological information

#### Information on toxicological effects

**Acute toxicity** 

Not available.

**Irritation/Corrosion** 

Not available.

**Sensitisation** 

Not available.

**Mutagenicity** 

**Conclusion/Summary** 

: Not available.

**Carcinogenicity** 

Conclusion/Summary :

: Not available.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 8/12

## **Section 11. Toxicological information**

Reproductive toxicity

Conclusion/Summary : Not available.

**Teratogenicity** 

**Conclusion/Summary** : Not available. Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

**Aspiration hazard** 

Not available.

Information on likely routes

of exposure

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator Not available. Not available.

No specific data.

Potential acute health effects

**Eye contact** 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell Activator No known significant effects or critical hazards. No known significant effects or critical hazards.

Inhalation : 2-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell Activator

No known significant effects or critical hazards. No known significant effects or critical hazards.

Skin contact : **2**-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell Activator No known significant effects or critical hazards. No known significant effects or critical hazards.

Ingestion 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell Activator No known significant effects or critical hazards. No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

**2**-deoxyglucose (2-DG) **Eye contact** No specific data.

ImmunoCult™ Human CD3/CD28 T Cell Activator

Inhalation **2**-deoxyglucose (2-DG) No specific data. No specific data.

ImmunoCult™ Human CD3/CD28 T Cell Activator

**Skin contact** : 2-deoxyglucose (2-DG) No specific data. No specific data.

ImmunoCult™ Human CD3/CD28 T Cell Activator

Ingestion : 2-deoxyglucose (2-DG) No specific data. ImmunoCult™ Human No specific data.

CD3/CD28 T Cell Activator

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

**Potential immediate** : Not available.

effects

Potential delayed effects : Not available.

Long term exposure

: Not available. Potential immediate

effects

Potential delayed effects Not available.

Potential chronic health effects

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version: 3.1 9/12

## **Section 11. Toxicological information**

General : 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell Activator No known significant effects or critical hazards. No known significant effects or critical hazards.

Carcinogenicity

: 2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator No known significant effects or critical hazards. No known significant effects or critical hazards.

Mutagenicity

2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator No known significant effects or critical hazards. No known significant effects or critical hazards.

Reproductive toxicity

: **Z**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator No known significant effects or critical hazards. No known significant effects or critical hazards.

# Numerical measures of toxicity Acute toxicity estimates

N/A

## Section 12. Ecological information

#### **Toxicity**

Not available.

#### Persistence and degradability

Not available.

#### **Bioaccumulative potential**

Not available.

#### **Mobility in soil**

Soil/water partition coefficient (Koc)

: Not available.

Other adverse effects : No known significant effects or critical hazards.

## Section 13. Disposal considerations

**Disposal methods** 

The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

## **Section 14. Transport information**

ADG / IMDG / IATA : Not regulated as Dangerous Goods according to the ADG Code .

Special precautions for user : Transport within user's premises: always transport in closed containers that are

upright and secure. Ensure that persons transporting the product know what to do in

the event of an accident or spillage.

Transport in bulk according : Not available.

to IMO instruments

## Section 15. Regulatory information

#### Standard for the Uniform Scheduling of Medicines and Poisons

Not regulated.

**Model Work Health and Safety Regulations - Scheduled Substances** 

No listed substance

#### International regulations

#### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

#### **Montreal Protocol**

Not listed.

#### Stockholm Convention on Persistent Organic Pollutants

Not listed.

#### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

#### **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

#### **Inventory list**

Australia : Not determined.

New Zealand : Not determined.

United States : Not determined.

## Section 16. Any other relevant information

#### **History**

Date of issue/Date of : 29/04/2024

revision

Date of previous issue : 27/10/2023

Version : 3.1

**Key to abbreviations** : ADG = Australian Dangerous Goods

ADR = The European Agreement concerning the International Carriage of

Dangerous Goods by Road ATE = Acute Toxicity Estimate BCF = Bioconcentration Factor

GHS = Globally Harmonized System of Classification and Labelling of Chemicals

IATA = International Air Transport Association

IBC = Intermediate Bulk Container

IMDG = International Maritime Dangerous Goods

LogPow = logarithm of the octanol/water partition coefficient

MARPOL = International Convention for the Prevention of Pollution From Ships,

1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)

N/A = Not available

SUSMP = Standard Uniform Schedule of Medicine and Poisons

UN = United Nations

 Date of issue/Date of revision
 : 29/04/2024
 Date of previous issue
 : 27/10/2023
 Version
 : 3.1
 11/12

Seahorse XF Hu T Cell Activation Assay Kit

# Section 16. Any other relevant information

### Procedure used to derive the classification

Classification

Not classified.

✓ Indicates information that has changed from previously issued version.

#### **Notice to reader**

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 12/12